Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Lucy M Carter"'
Autor:
John A Reynolds, Edward Vital, Miriam Wittmann, Zoe Wigston, Yuzaiful Yusof, Agata Burska, Adewonuola Alase, Lucy M Carter, Antony Psarras
Publikováno v:
Lupus Science and Medicine, Vol 8, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/89abb2bf4bcf4ab1b9363536eccd239c
Autor:
Mumina Akthar, Nisha Nair, Lucy M. Carter, Edward M. Vital, Emily Sutton, Neil McHugh, British Isles Lupus Assessment Group Biologics Register (BILAG BR) Consortium, MASTERPLANS Consortium, Ian N. Bruce, John A. Reynolds
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-12 (2023)
Abstract Background Systemic lupus erythematosus (SLE) is a clinically and biologically heterogeneous autoimmune disease. We explored whether the deconvolution of whole blood transcriptomic data could identify differences in predicted immune cell fre
Externí odkaz:
https://doaj.org/article/2d701c0a7c254045b660d9c0af1f753c
Autor:
Mumina Akthar, Nisha Nair, Lucy M. Carter, Edward M. Vital, Emily Sutton, Neil McHugh, British Isles Lupus Assessment Group Biologics Register (BILAG BR) Consortium, MASTERPLANS Consortium, Ian N. Bruce, John A. Reynolds
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/bb267f36b9244d8e9092416d4e949840
Publikováno v:
British Journal of Dermatology.
Background Observations with rituximab suggest B-cell independent mechanisms of cutaneous lupus (CLE) in SLE, especially discoid. Type-I interferon receptor blockade with anifrolumab shows efficacy in SLE but efficacy on cutaneous disease of specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8e05a836acdec315de7d0052a1deed9
https://doi.org/10.1093/bjd/ljad089
https://doi.org/10.1093/bjd/ljad089
Autor:
Lucy M, Carter, Adewonuola, Alase, Zoe, Wigston, Antony, Psarras, Agata, Burska, Emily, Sutton, Md Yuzaiful, Md Yusof, John A, Reynolds, Neil, McHugh, Paul, Emery, Miriam, Wittmann, Ian N, Bruce, Edward M, Vital
Publikováno v:
Arthritisrheumatology (Hoboken, N.J.).
Gene expression profiles are associated with the clinical heterogeneity of SLE but are not well studied as biomarkers for therapy. Many clinical and demographic features influence treatment responses. We studied gene expression and response to rituxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ae6c7654b6d86512f3f7168e80d2154
https://pubmed.ncbi.nlm.nih.gov/36409591
https://pubmed.ncbi.nlm.nih.gov/36409591
Autor:
Paul Emery, John A Reynolds, A. Psarras, Miriam Wittmann, Adewonuola Alase, Lucy M. Carter, Yuzaiful Md Yusof, Zoe Wigston, IN Bruce, Edward M. Vital, Agata Burska
Publikováno v:
Lupus Science and Medicine, Vol 8, Iss Suppl 2 (2021)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cab3bf4c08fb4207659d9c4661c7881a
https://doi.org/10.1136/lupus-2021-lupus21century.95
https://doi.org/10.1136/lupus-2021-lupus21century.95
Autor:
Sarah Skeoch, Ian N. Bruce, David A. Isenberg, Lucy M Carter, Chee Seng Yee, Edward M Vital, Caroline Gordon
Publikováno v:
Rheumatology (Oxford, England). 61(10)
Objective BILAG-2004 index is a comprehensive disease activity instrument for SLE but administrative burden and potential frequency of errors limits its use in routine practice. We aimed to develop a tool for more accurate, time-efficient scoring of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7556231f0bce240f9bcee370d24de80
https://pubmed.ncbi.nlm.nih.gov/35171270
https://pubmed.ncbi.nlm.nih.gov/35171270
Autor:
Ian N. Bruce, Khaled F. Mahmoud, Sabih Ul Hassan, Edward M Vital, Neil McHugh, Anthony Psarras, Lucy M. Carter, Paul Emery, Yuzaiful Md Yusof, Danyang Li, Katherine Dutton, Zoe Wigston
Publikováno v:
Rheumatology. 60
Background/Aims SLE is heterogeneous in clinical presentation, underlying immunology, and response to therapy. Patients with severe or resistant disease receive cyclophosphamide or rituximab. Although effective, late use of these therapies entails cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::979247b06dd57faf41a20786c85392fa
https://doi.org/10.1093/rheumatology/keab247.159
https://doi.org/10.1093/rheumatology/keab247.159
Autor:
Kuljeet Bhamra, Adnan D’Cunha Kamath, Patrick Hanna, Hannah Irvine, Lucy M Carter, Naim Rahimi, Ankita Sahni
Publikováno v:
Rheumatology (Oxford, England)
Background/Aims Individuals on immunosuppressive therapies were among those identified by the UK Department of Health and Chief Medical Officer as clinically extremely vulnerable to COVID-19. Advice on shielding from infection was disseminated by NHS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5f349727a3116854c79edb5b2c2a2de
https://doi.org/10.1093/rheumatology/keab247.056
https://doi.org/10.1093/rheumatology/keab247.056
Autor:
Chee-Seng Yee, Caroline Gordon, Edward M Vital, Sarah Skeoch, David A. Isenberg, Lucy M Carter, Ian N. Bruce
Publikováno v:
Rheumatology. 60
Background/Aims BILAG-2004 index is required to prescribe and monitor biologics in SLE. It is more comprehensive and responsive than the SLEDAI and widely used in clinical trials. However, it may be time-consuming and does require training for accura
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc24786a30d44ff0f2593234dcbd1ecb
https://doi.org/10.1093/rheumatology/keab246.018
https://doi.org/10.1093/rheumatology/keab246.018